FGF21 Frontier in Clinically Significant MASH

New therapies are reshaping care for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with F2–F3 fibrosis, yet compensated cirrhosis remains a frontier with no approved pharmacologic option. Fibroblast growth factor 21 (FGF21) analogues are a closely watched investigational class targeting both metabolic dysfunction and fibrosis. The science is outpacing the literature that explains it: FGF21 biology, the agents in the class, and how to read the evolving trial data still sit mostly in congress presentations and primary reports. This activity brings it together for hepatology and gastroenterology clinicians, NPs, and PAs — a timely grounding in FGF21 biology, the latest evidence for FGF21 analogues, and the rationale for investigating this pathway in compensated cirrhosis.

In this CME Outfitters Snack, expert faculty will assist learners to explore the role of FGF21 across metabolic and fibrotic pathways, interpret emerging clinical evidence for FGF21 analogues in clinically significant MASH, and examine the scientific rationale for targeting the FGF21 pathway in patients with compensated cirrhosis due to MASH.

At the conclusion of this activity, learners will be able to better:

• Evaluate the biology of FGF21 within metabolic and fibrotic pathways
• Assess emerging clinical evidence for FGF21 analogues in clinically significant MASH
• Appraise the rationale for FGF21-pathway therapy in compensated cirrhosis due to MASH

Supported by an educational grant from Novo Nordisk Inc.

Hepatology and gastroenterology clinicians (MDs/DOs), nurse practitioners (NPs), and physician associates (PAs)

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Faculty

Dr. Kowdley reports the following financial relationships:

Advisory Board: Inipharm

Consultant: 89bio, Inc.; CymaBay Therapeutics; Genfit; Gilead Sciences, Inc.; HighTide Therapeutics, Inc.; Inipharm; Intercept Pharmaceuticals, Inc.; Ipsen Pharma; Kowa Pharmaceuticals America, Inc.; Madrigal Pharmaceuticals, Inc.; Mirum Pharmaceuticals; NGM; Boehringer Ingelheim; and Zydus Pharmaceuticals, Inc.

Research Support: 89bio, Inc.; AstraZeneca; Boston Pharmaceutical Industries; Boehringer Ingelheim; Corcept Therapeutics, Incorporated; CymaBay Therapeutics; Gilead Sciences, Inc.; GSK; Hanmi Pharmaceutical; HighTide Therapeutics, Inc.; Ipsen Pharma; Kowa Pharmaceuticals America, Inc.; Madrigal Pharmaceuticals, Inc.; Mirum Pharmaceuticals; Novo Nordisk; NGM Biopharmaceuticals; Pfizer Inc.; Pliant Therapeutics, Inc.; Terns Pharmaceuticals; Viking Therapeutics; and Zydus Pharmaceuticals, Inc.

Speakers Bureau: Gilead, Sciences, Inc.; Ipsen Pharma; Madrigal Pharmaceuticals, Inc.; and Novo Nordisk

Dr. Rinella reports the following financial relationships:

Consultant: Akero Therapeutics, Inc.; Altimmune; 89Bio, Inc.; Boehringer Ingelheim International GmbH; CytoDyn Inc.; GSK plc.; Hepta Bio.; Histoindex Pte Ltd.; Intercept Pharmaceuticals, Inc.; Inventina; Lilly; Madrigal Pharmaceuticals, Inc.; NGM Biopharmaceuticals; Novo Nordisk A/S; Sagimet Biosciences; Sonic Incytes; Regeneron Pharmaceuticals Inc.; and F. Hoffman-La Roche Ltd

Patient Planner

Susan Horava reports the following financial relationships:

Other financial or material support: Madrigal Pharmaceuticals, Inc.

The following individuals have no financial relationships to disclose:

Thai Nguyen, MD, MHA (Peer Reviewer)
Jessica Giddens, DNP, APRN, FPMHNP-BC, RN-BC (Peer Reviewer)
Mary Gleason, PhD, CHCP (Planning Committee)
Warren Beckman (Planning Committee)
Andrea Perseghin, EdD (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required). This website supports all browsers except Internet Explorer for Mac.

Call us at 877.CME.PROS (877.263.7767).

SN-318-100926-68